BioArctic AB (publ) (BRCTF) Q1 2026 Earnings Call May 20, 2026 3:30 AM EDT
Company Participants
Gunilla Osswald - President & CEO
Johanna Fälting - Chief R&D Officer and Head of Research & Development
Anna-Kaija Gronblad - Chief Commercial Officer & Head of Commercial Operations
Anders Martin-Lof - Secretary of the Board & CFO
Conference Call Participants
Joseph Hedden - Rx Securities Limited, Research Division
Suzanne van Voorthuizen - Kempen & Co. N.V., Research Division
Rajan Sharma - Goldman Sachs Group, Inc., Research Division
Natalia Webster - RBC Capital Markets, Research Division
Presentation
Operator
Welcome to BioArctic Q1 Report 2026. [Operator Instructions]
Now I will hand the conference over to CEO, Gunilla Osswald, with colleagues. Please go ahead.
Gunilla Osswald
President & CEO
Good morning, and welcome to BioArctic's presentation for the first quarter of 2026. It has been a strong start of the year for BioArctic following a transformative year of 2025 with record financial results. It shows that the growth ear continues in a great way for BioArctic. It's reassuring to see that more and more patients are getting access to Leqembi, and we had more than EUR 500 million of sales during our partner Eisai's fiscal year and that resulted in a commercial milestone to BioArctic. Our projects and our BrainTransporter technology are also progressing really well. And we have an increased focus on business development, which is based on great interest in BrainTransporter and in our projects. I'll talk more about that in today's presentation.
Next slide, please. BioArctic is listed at Nasdaq Stockholm Large Cap, and this is our disclaimer.
Next slide, please. So I'm Gunilla Osswald, and I'm the CEO of BioArctic, and I will share today's presentation with our CFO, Anders Martin-Lof; and our Chief R&D Officer, Johanna Falting; and our Chief Commercial Officer, Anna-Kaija Gronblad.
Next
此内容由惯性聚合(RSS阅读器)自动聚合整理，仅供阅读参考。 原文来自 — 版权归原作者所有。